NanoVibronix Inc. (NAOV): 2025 Product Pipeline and Strategy Analysis Report
Product Stage
NanoVibronix Launches "Oscar" Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities
Product StageCustomers
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PIPE/PO
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
Product Stage
NanoVibronix Announces Reverse Stock Split
NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock
Investment
NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation
Product Stage
NanoVibronix’s ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement
CustomersProduct Stage
ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System
Product Stage
NanoVibronix Announces CEO Transition
Management ChangesAcquisition
Major Louisiana Hospital Selects ENvue System for Feeding Tube Procedures
Customers
NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants
PIPE/PO
NanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants
PIPE/PO
NanoVibronix Announces Results from UroShield™ Case Series
Product Stage
NanoVibronix Regains Nasdaq Compliance
NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia
Partners
Why Nanovibronix Inc. (NAOV) Surged On Thursday?
Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal
NanoVibronix Announces Reverse Stock Split